Acrux Ltd has released a press release.
Appendix 4E and FY23 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Acrux
- Activities Statement and Appendix 4C
- Acruxs seventh generic dossier accepted by FDA for review
- 4th FDA ANDA approval received - Dapsone Gel, 5%
- Appendix 4D and Half Year Report
- Quarterly Activities / Appendix 4C Cashflow Report
Later from Acrux
- Investor Presentation - Acrux FY23 Results
- Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
- Address of Chair and CEO to AGM
- Appendix 4C and Activities Statement
- Appendix 4D and Half Year Accounts
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux